Trial intelligence / Profile preview

Erlotinib plus gemcitabine/platinum vs placebo plus gemcitabine/platinum in advanced NSCLC (China)

CTR20140049Phase 3Active

Sponsor
Roche
Start
Oct 2014
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Oct 2014; status: active.

02

Drugs

erlotinib
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on CTR20140049.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20140049.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call